Tagged with

Puerto Rico HRP Labs, the largest operator of pathology and specialized laboratories in Puerto Rico, is leading the way in the post-Hurricane Maria industry. Guillermo Villarmarzo, in-house legal counselor, and Gabriela Villarmarzo, chief compliance officer, discuss the company’s strategy to continue serving Puerto Rico’s healthcare system in benefit of the patients and…

Hungary Dr. György Blaskó, former President and Chairman of the Hungarian European Clinical Research Infrastructure Network, explains the role of the research network, the impact it has on the Hungarian clinical research environment, and the areas of improvement moving forward.   Domestic centralized health care and the presence of a single…

China PharmaBoardroom recently analysed the contents of 10 interviews conducted with country managers at multinational pharma companies in China. We found some underlying themes present in the majority of the interviews, giving an exclusive glimpse into what is currently at the top of the minds of pharma country managers in China.…

Puerto Rico After Hurricane Maria hit Puerto Rico in 2017, its infrastructure was left severely damaged. CMA, one of the island’s premiere architecture and engineering firms, has been working on reconstruction ever since. Jorge Tirado, CMA’s managing partner, describes how the company has managed to become the go-to firm for the pharma…

Czech Republic Martin Mátl, executive director of the Czech Association of Pharmaceutical Companies (ČAFF), shares the key priorities and challenges of the association and its members; assesses the Czech generics ecosystem, and gives insight into the importance of generics in providing a sustainable healthcare environment with ready availability of medicines for patients.…

Hungary Dr. György Bagdy, professor and former vice rector at Semmelweis University, shares his insights on the longstanding history of pharmacology in Hungary, the key strengths of the country in the field of neuroscience, and the future outlook of a more collaborative and innovation-focused research landscape.   Hungary has the knowledge…

China Dr. Zhang Yu, CEO of Aeon Therapeutics, shares the unique journey that motivated him to establish Aeon Therapeutics, as a joint venture of Chinese VcanBio and US-based Eureka Therapeutics, to commercialize Eureka’s assets in China and to tackle one of the biggest challenges facing the global CAR-T industry: the difficulty…

Puerto Rico Based in Tampa, Florida, Romark is a research-based pharmaceutical company focused on developing innovative treatments for infectious diseases. The company recently inaugurated its first finished products manufacturing facilities in Puerto Rico, transforming itself into a vertically integrated organization. CEO Marc Ayers extols the strengths of Puerto Rico as manufacturing location…

Hungary Hungarian national champion Egis and French Big Pharma Sanofi have both made recent big-ticket investments in new facilities in Hungary. Egis’ new manufacturing plant in Körmend and Sanofi’s new shared service centre in Budapest respectively stand to have a sizeable impact on the local economies and show the increasing attractiveness…

China With proactive government support and an increasingly specialised workforce, China has become one of the leading nations in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies, along with the US. More than 200 CAR-T therapies are being developed in China, and the number of ongoing clinical trials continues to…

Thailand PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Thailand is available for download now.   Thailand is in the midst of an economic transformation with healthcare at its heart. With four years of around three-four percent annual GDP growth behind it, ASEAN’s second-largest economy has implemented an ‘Industry 4.0’ policy through which…

Opinion Michael Jewell, partner and head of healthcare & life sciences at Cavendish Corporate Finance looks back at the key trends across pharma industry funding in 2019 and gives his perspective on how 2020 will look.   As we approach the end of 2019, it’s a good time to look back…